Skip to search formSkip to main contentSkip to account menu

NSC 663284

Known as: NSC-663284, NSC663284 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Cdc25 phosphatase B, a potential target for cancer therapy, is inhibited by a series of quinones. The binding site and mode of… 
2013
2013
There-fore, the finding and developing of the specific inhibitorsthat target protein phosphatase or kinases are essential… 
2013
2013
Background: Docetaxel is the standard treatment for metastatic castration-resistant prostate cancer (CRPC) since 2004 and overall… 
2005
2005
660 Cdc25 dual specificity phosphatases are overexpressed in many human tumors and have oncogenic properties. Although several… 
2004
2004
Cdc25 dual-specificity phosphatases coordinate cell cycle progression and cellular signaling. Consequently, Cdc25 inhibitors… 
2004
2004
Cdc25 dual-specificity phosphatases coordinate cell cycle progression and cellular signaling. Consequently, Cdc25 inhibitors… 
Highly Cited
2004
Highly Cited
2004
Survivin is expressed in most tumor cells and has been associated with both anti-apoptosis and mitotic progression. However, the…